While Japan's companies are stepping up their overseas asset buying, the company behind the biggest cross-border deal this year, Takeda Pharmaceutical Co., said it has no near-term plans for another mega-M&A deal. Yasuchika Hasegawa, the president of the country's No. 1 drug maker by sales and also chairman of one of Japan's largest business groups, said that having bought Switzerland's Nycomed, his company is now focusing on a delicate part of the M&A process that many companies have trouble tackling successfully—integrating acquisitions.
